- Home
- SXTP vs CERO Comparison
SXTP vs CERO Comparison
Compare SXTP & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- CERO
- Stock Information
- Founded
- SXTP 2010
- CERO 2017
- Country
- SXTP United States
- CERO United States
- Employees
- SXTP N/A
- CERO N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- SXTP Health Care
- CERO
- Exchange
- SXTP Nasdaq
- CERO Nasdaq
- Market Cap
- SXTP 2.7M
- CERO 3.1M
- IPO Year
- SXTP 2023
- CERO N/A
- Fundamental
- Price
- SXTP $2.47
- CERO $0.59
- Analyst Decision
- SXTP Hold
- CERO Strong Buy
- Analyst Count
- SXTP 1
- CERO 1
- Target Price
- SXTP N/A
- CERO $11.00
- AVG Volume (30 Days)
- SXTP 186.6K
- CERO 4.2M
- Earning Date
- SXTP 05-15-2025
- CERO 05-27-2025
- Dividend Yield
- SXTP N/A
- CERO N/A
- EPS Growth
- SXTP N/A
- CERO N/A
- EPS
- SXTP N/A
- CERO N/A
- Revenue
- SXTP $802,323.00
- CERO N/A
- Revenue This Year
- SXTP $95.50
- CERO N/A
- Revenue Next Year
- SXTP $80.78
- CERO N/A
- P/E Ratio
- SXTP N/A
- CERO N/A
- Revenue Growth
- SXTP 118.37
- CERO N/A
- 52 Week Low
- SXTP $1.41
- CERO $0.53
- 52 Week High
- SXTP $36.00
- CERO $147.00
- Technical
- Relative Strength Index (RSI)
- SXTP 50.12
- CERO 36.01
- Support Level
- SXTP $2.10
- CERO $0.55
- Resistance Level
- SXTP $2.47
- CERO $0.62
- Average True Range (ATR)
- SXTP 0.24
- CERO 0.06
- MACD
- SXTP -0.04
- CERO -0.01
- Stochastic Oscillator
- SXTP 46.84
- CERO 7.74
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.